Next Article in Journal
Cancer Mechanisms and Emerging Therapies
Next Article in Special Issue
Therapeutic Development Based on the Immunopathogenic Mechanisms of Psoriasis
Previous Article in Journal
Glucuronides Hydrolysis by Intestinal Microbial β-Glucuronidases (GUS) Is Affected by Sampling, Enzyme Preparation, Buffer pH, and Species
Previous Article in Special Issue
The Stimulating Effect of Rosmarinic Acid and Extracts from Rosemary and Lemon Balm on Collagen Type I Biosynthesis in Osteogenesis Imperfecta Type I Skin Fibroblasts
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceutics
Volume 13
Issue 7
10.3390/pharmaceutics13071044
pharmaceutics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream

by
Paul Smith
1,*,
Wenqing Yao
2,
Stacey Shepard
1,
Maryanne Covington
1,
Jim Lee
2,
Jennifer Lofland
2,
Ahmad Naim
2,
Trupti Sheth
2,
Bhavnish Parikh
2 and
Swamy Yeleswaram
1
1
Incyte Research Institute, 1801 Augustine Cut-Off, Wilmington, DE 19803, USA
2
Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, DE 19803, USA
*
Author to whom correspondence should be addressed.
Pharmaceutics 2021, 13(7), 1044; https://doi.org/10.3390/pharmaceutics13071044
Submission received: 28 May 2021 / Revised: 30 June 2021 / Accepted: 6 July 2021 / Published: 8 July 2021
(This article belongs to the Special Issue Skin Immunomodulation: Impact on Diseases and Treatments)
Browse Figures
Versions Notes

Abstract

Named after the two-faced Roman god of doorways, Janus kinases (JAKs) represent a class of tyrosine kinases. The JAK signaling pathway is pivotal for the downstream signaling of inflammatory cytokines, including interleukins, interferons, and multiple growth factors. This article provides an overview of the JAK pathway and signaling, its significance in immune-mediated dermatologic diseases and the development of a targeted, localized option of a selective JAK inhibitor, ruxolitinib cream. In the early 1990s, various discovery and clinical development programs were initiated to explore pharmaceutical inhibition of the JAK-STAT pathway. Incyte Corporation launched a strategy to identify molecules suitable for both topical as well as oral delivery. Ruxolitinib was designed as a molecule with low nanomolar potency selective for JAK1 and 2 enzymes, but without significant inhibition of non-JAK kinases, as well as physicochemical properties for both topical and oral administration. An oil-in-water emulsified ruxolitinib cream formulation was developed for topical application and was studied in multiple immune-mediated dermatologic diseases including psoriasis, alopecia areata, atopic dermatitis and vitiligo. Ruxolitinib cream represents a novel, JAK1/2 selective therapy that can be delivered directly to the skin to treat a number of cytokine-driven, inflammatory dermatoses.
Keywords: Janus kinase; inflammation; atopic dermatitis; vitiligo; topical Janus kinase; inflammation; atopic dermatitis; vitiligo; topical

Share and Cite

MDPI and ACS Style

Smith, P.; Yao, W.; Shepard, S.; Covington, M.; Lee, J.; Lofland, J.; Naim, A.; Sheth, T.; Parikh, B.; Yeleswaram, S. Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream. Pharmaceutics 2021, 13, 1044. https://doi.org/10.3390/pharmaceutics13071044

AMA Style

Smith P, Yao W, Shepard S, Covington M, Lee J, Lofland J, Naim A, Sheth T, Parikh B, Yeleswaram S. Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream. Pharmaceutics. 2021; 13(7):1044. https://doi.org/10.3390/pharmaceutics13071044

Chicago/Turabian Style

Smith, Paul, Wenqing Yao, Stacey Shepard, Maryanne Covington, Jim Lee, Jennifer Lofland, Ahmad Naim, Trupti Sheth, Bhavnish Parikh, and Swamy Yeleswaram. 2021. "Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream" Pharmaceutics 13, no. 7: 1044. https://doi.org/10.3390/pharmaceutics13071044

APA Style

Smith, P., Yao, W., Shepard, S., Covington, M., Lee, J., Lofland, J., Naim, A., Sheth, T., Parikh, B., & Yeleswaram, S. (2021). Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream. Pharmaceutics, 13(7), 1044. https://doi.org/10.3390/pharmaceutics13071044

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop